メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
岸 太郎
精神神経科学
h-index
5849
被引用数
43
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2006
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(253)
類似のプロファイル
(6)
フィンガープリント
Taro Kishiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Neuroscience
Meta-Analysis
100%
Dementia Praecox
97%
Major Depressive Disorder
83%
Typical Antipsychotic
37%
Mood Disorder
27%
Placebo
27%
Receptor Gene
25%
Randomized Controlled Trial
22%
Brain-Derived Neurotrophic Factor
21%
Bipolar Disorder
20%
Methamphetamine-Induced Psychosis
19%
Antidepressant
16%
Haplotype
15%
Antipsychotic
15%
Aripiprazole
14%
Fluvoxamine
13%
Negative Syndrome
12%
5-HT6 Receptor
12%
Selective Serotonin Reuptake Inhibitor
12%
Risperidone
12%
Positive Syndrome
11%
Olanzapine
10%
Alzheimer's Disease
9%
5-HT1A Receptor
9%
Nuclear Receptor NR1D1
9%
Memantine
9%
Treatment of Schizophrenia
7%
Cognitive Function
7%
Dorsolateral Prefrontal Cortex
7%
CHRNA4
7%
Hamilton Rating Scale for Depression
7%
Bipolar Depression
6%
Startle Response
6%
Quetiapine
6%
Prokineticin
6%
Nuclear Receptor
6%
Catecholamine
6%
Circadian Rhythm
6%
Haloperidol
6%
Voxel-Based Morphometry
6%
Suvorexant
6%
DNA Polymorphism
6%
Neu Differentiation Factor
6%
Lurasidone
6%
Factor X
6%
Lewy Body
6%
Methyltransferase
6%
Mirtazapine
5%
Depression
5%
Psychosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
52%
Typical Antipsychotic
33%
Antipsychotic
33%
Randomized Controlled Trial
31%
Adverse Event
27%
Aripiprazole
27%
Major Depression
23%
Alzheimer's Disease
19%
Disease
18%
Blonanserin
18%
Olanzapine
16%
Negative Syndrome
16%
Memantine
15%
Remission
15%
Risperidone
14%
Quetiapine
13%
Positive Syndrome
12%
Bipolar Depression
12%
Symptom
12%
Paliperidone
11%
Lurasidone
10%
Recurrence Risk
10%
Brexpiprazole
10%
Tolerability
8%
Perospirone
8%
Bipolar Disorder
8%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
7%
Random Effects Model
7%
Clozapine
6%
Headache
6%
Delirium
6%
Yokukansan
6%
Add on Therapy
6%
Monotherapy
5%
Depression
5%
Nootropic Agent
5%
Keyphrases
Meta-analysis
41%
Major Depressive Disorder
35%
Systematic Meta-analysis
24%
Japanese Population
16%
Gene Disorders
13%
Schizophrenia
13%
Network Meta-analysis
9%
Confidence Interval
9%
Brain-derived Neurotrophic Factor
9%
Alzheimer's Disease
9%
Intermittent theta Burst Stimulation (iTBS)
9%
Randomized Placebo-controlled Trial
9%
Non-associated
8%
Standardized Mean Difference
7%
Risk Ratio
7%
Association Study
7%
Mood Disorders
6%
HF-rTMS
6%
Aripiprazole
6%
Adverse Events
6%
Serotonin 6 Receptor
6%
Serotonin-1A Receptor
6%
Protease-activated Receptor 4 (PAR4)
6%
Receptor Gene
6%
Aripiprazole Once-monthly
6%
Translin
6%
X Gene
6%
SIRT1 Gene
6%
Methamphetamine-induced Psychosis
6%
Memantine
6%
Meta-analysis of Randomized Controlled Trials
6%
Lurasidone
6%
Treatment-resistant Depressive Disorder
6%
Newer Antidepressants
6%
Bipolar Disorder
6%
Placebo
6%
Genotype
5%
Pathophysiology
5%
Antidepressants
5%
Left DLPFC
5%
